ASBM/GaBI Biosimilar Webinar Series 2022

Home/Conferences | Posted 03/06/2022 post-comment0 Post your comment

Overview of Non-Medical Switching Practices in Different Regions and the Importance of Safeguarding the Physician–Patient Relationship
20 July 2022 | 10:00 am – 12:00 pm (EDT)

ASBM 2022 Webinar 2 Banner Square V22F30AU

2nd ASBM/GaBI biosimilar webinar on non-medical switching
20 July 2022 | 10:00 am – 12:00 pm (EDT)

The advent of biologicals offers significant benefits and enhanced quality of life for patients with chronic diseases, such as rheumatoid arthritis, multiple sclerosis and cancer. However, finding a working treatment regimen may take a long time and involves trial and error for a patient’s individual case.

Nevertheless, government policies that force biosimilar switching for non-medical and strictly economic reasons may ultimately affect patients’ treatment and their well-being, create mistrust in the healthcare system, undermine competition, increase total healthcare costs, and act as a barrier to innovation and future access to new biological drugs for patients.

Non-medical switching should consider two governing principles: 1) the physician–patient relationship must be protected to ensure the best outcomes; and 2) patients stabilized on a biological therapy should not be forced to undergo a non-medical switch.

In this online event, we would like to share the expert experience and knowledge on medical switching and principles and guidance on interchangeability of biologicals/biosimilars, highlighting the specific concerns on, and the importance of a multi-stakeholder approach protecting the physician–patient relationship in the practice of non-medical switching of biologicals/biosimilars.

We invite you to join us on 20 July 2022 – 10:00 am to 12:00 pm EDT.

The First Webinar on KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US had 244 registrants/attendees; seats are limited to 250 in this 2nd webinar on non-medical switching of biologicals/biosimilars. REGISTER NOW! Don’t miss out!

Michael S Reilly, Esq, Executive Director, Alliance for Safe Biologic Medicines
Gail Attara, President & Chief Executive Officer, Gastrointestinal Society, Canada
Ralph McKibbin, MD, FACP, FACG, AGAF, President of the Pennsylvania Society of Gastroenterology and the Digestive Disease National Coalition
Leah Christl, PhD, Amgen, USA (Former FDA Director at CDER)
Andrew Spiegel, Esq, Executive Director, Global Colon Cancer Association
Retinal specialist/patient – to be advised

Download full programme and Register NOW!

Online event hosted by the Alliance For Safe Biologic Medicines and Generics and Biosimilars Initiative

ASBM–GABI Biosimilar Webinar Series
This webinar is the second in a series. The discussion will continue at the next webinar on ‘Ophthalmic Biosimilars' in September 2022. More information will be available soon.

ASBM 2022 Webinar 2 Banner e-blast V22F30AU
comment icon Comments (0)
Post your comment
Related content
AAM GRx+Biosims 2022
Home/Conferences Posted 01/04/2022
DIA Biosimilars USA 2022
Home/Conferences Posted 18/03/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010